Alcoholic liver disease: State-of-the-art

Cite item

Full Text


The literature review gives the present views of the diagnosis and treatment of alcoholic liver disease (ALD) and data on the genetic markers associated with the development of ALD and alcohol addiction. It discusses in detail the mechanisms of liver damage within the disease in question and substantiates indications for the use of prednisolone and pentoxifylline in alcoholic hepatitis. Therapeutic approaches to treating different forms of ALD are considered.

Full Text

Алкогольная болезнь печени: современное состояние проблемы. - Аннотация. В обзоре литературы представлены современные взгляды на диагностику и лечение алкогольной болезни печени (АБП). Приведены данные о генетических маркерах, ассоциированных с развитием АБП и алкогольной зависимостью. Подробно обсуждены механизмы поражения печени в рамках рассматриваемого заболевания. Обосновываются показания к применению преднизолона и пентоксифиллина при алкогольном гепатите. Рассмотрены терапевтические подходы к лечению различных форм АБП.


  1. Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol 2011; 45: 714-719.
  2. Rehm J., Mathers C., Popova S. et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373 (9682): 2223-2233.
  3. Заграев Г.Г. Алкоголизм и пьянство в России. Пути выхода из кризисной ситуации. Социол исслед 2009; 8: 74-84.
  4. Lieber C.S., Jones D.P., Decarli L.M. Effects of Prolonged Ethanol Intake: Production of Fatty Liver Despite Adequate Diets. J Clin Invest 1965; 44: 1009-1021.
  5. Helman R.A., Temko M.H., Nye S.W., Fallon H.J. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971; 74 (3): 311-321.
  6. Гастроэнтерология. Национальное руководство: краткое издание. Под. ред В.Т. Ивашкина, Т.Л. Лапиной. М: ГЭОТАР-Медиа 2011; 480.
  7. Bruha R., Dvorak K., Petrtyl J. Alcoholic liver disease. World J Hepatol 2012; 4 (3): 81-90.
  8. Menon K.V., Gores G.J., Shah V.H. Pathogenesis, diagnosis, and treatment of alcoholic liver disease. Mayo Clin Proc 2001; 76 (10): 1021-1029.
  9. Bosetti C., Levi F., Lucchini F. et al. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46 (5): 827-839.
  10. Carithers R.L., McClain C. Alcoholic liver disease. In: Feldman M., Friedman L.S., Brandt L.J. Feldman: Sleisinger & Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2010: chap 84.
  11. Becker U., Deis A., Sørensen T.I. et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23 (5): 1025-1029.
  12. O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology 2010; 51: 307-328.
  13. Wilfred de Alwis N.M., Day C.P. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27: 44-54.
  14. Juran B.D., Lazaridis K.N. Genomics and complex liver disease: Challenges and opportunities. Hepatology 2006; 44: 1380-1390.
  15. Whitfield J.B. Meta-analysis of the effects of alcohol dehydrogenase genotype on alcohol dependence and alcoholic liver disease. Alcohol Alcohol 1997; 32: 613-619.
  16. Valenti L., De Feo T., Fracanzani A.L. et al. Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. Alcohol Alcohol 2004; 39: 276-280.
  17. Trépo E., Gustot T., Degré D. et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011; 55 (4): 906-912.
  18. Arteel G., Marsano L., Mendez C. et al. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol 2003; 17: 625-647.
  19. Baldini M., Lohman I.C., Halonen M. et al. A polymorphism in the 5' flankingregion of the CD14 gene is associated with circulating soluble CD14 levelsand with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20: 976-983.
  20. Siu L., Foont J., Wands J.R. Hepatitis C virus and alcohol. Semin Liver Dis 2009; 29 (2): 188-199.
  21. Raynard B., Balian A., Fallik D. et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35 (3): 635-638.
  22. Naveau S., Giraud V., Borotto E. et al. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25 (1): 108-111.
  23. Corrao G., Lepore A.R., Torchio P. et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease. Eur J Epidemiol 1994; 10 (6): 657-664.
  24. Pessione F., Ramond M.J., Njapoum C. et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001; 34 (1): 121-125.
  25. Rang H.P., Dale M.M., Ritter J.M., Flower R.J. Rang and Dale’s pharmacology. London: Elsevier Churchill Livingstone; 2007.
  26. Arteel G.E. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 2003; 124: 778-790.
  27. Farfán Labonne B.E., Gutiérrez M., Gómez-Quiroz L.E. et al. Acetaldehyde-induced mitochondrial dysfunction sensitizes hepatocytes to oxidative damage. Cell Biol Toxicol 2009; 25 (6): 599-609.
  28. Setshedi M., Wands J.R., Monte S.M. Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev 2010; 3 (3): 178-185.
  29. Thiele G.M., Worrall S., Tuma D.J. et al. The chemistry and biological effects of malondialdehyde-acetaldehyde adducts. Alcohol Clin Exp Res 2001; 25 (5 Suppl ISBRA): 218S-224S.
  30. Mello T., Ceni E., Surrenti C., Galli A. Alcohol induced hepatic fibrosis: role of acetaldehyde. Mol Aspects Med 2008; 29 (1-2): 17-21.
  31. Arteel G., Marsano L., Mendez C. et al. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol 2003; 17 (4): 625-647.
  32. Gao B., Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141 (5): 1572-1585.
  33. You M., Fischer M., Deeg M.A., Crabb D.W. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem 2002; 277 (32): 29342-29347.
  34. Peng Z., Borea P.A., Varani K. et al. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 2009; 119 (3): 582-594.
  35. Jeong W.I., Osei-Hyiaman D., Park O. et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008; 7 (3): 227-235.
  36. Ji C., Deng Q., Kaplowitz N. Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology 2004; 40 (2): 442-451.
  37. You M., Matsumoto M., Pacold C.M. et al. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 2004; 127 (6): 1798-1808.
  38. You M., Liang X., Ajmo J.M., Ness G.C. Involvement of mammalian sirtuin 1 in the action of ethanol in the liver. Am J Physiol Gastrointest Liver Physiol 2008; 294 (4): G892-G898.
  39. You M., Rogers C.Q. Adiponectin: a key adipokine in alcoholic fatty liver. Exp Biol Med (Maywood) 2009; 234 (8): 850-859.
  40. Horiguchi N., Wang L., Mukhopadhyay P. et al. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. Gastroenterology 2008; 134 (4): 1148-1158.
  41. Wagner M., Zollner G., Trauner M. Nuclear receptors in liver disease. Hepatology 2011; 53 (3): 1023-1034.
  42. Galli A., Pinaire J., Fischer M. et al. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver. J Biol Chem 2001; 276 (1): 68-75.
  43. Lu Y., Zhuge J., Wang X. et al. Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. Hepatology 2008; 47 (5): 1483-1494.
  44. McClain C.J., Song Z., Barve S.S. et al. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287 (3): G497-G502.
  45. Purohit V., Bode J.C., Bode C. et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 2008; 42 (5): 349-361.
  46. Wheeler M.D. Endotoxin and Kupffer cell activation in alcoholic liver disease. Alcohol Res Health 2003; 27 (4): 300-306.
  47. Luedde T., Schwabe R.F. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8 (2): 108-118.
  48. Lemmers A., Moreno C., Gustot T. et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49 (2): 646-657.
  49. Seki E., De Minicis S., Osterreicher C.H. et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13 (11): 1324-1332.
  50. Абдурахманов Д.Т. Алкогольный гепатит. Клин гепатол 2008; 4 (2): 3-10.
  51. Ивашкин В.Т. Болезни печени и желчевыводящих путей. Руководство для врачей. 2-е изд. М: Издательский дом М-Вести 2005.
  52. Маев И.В., Абдурахманов Д.Т., Дичева Д.Т. и др. Алкогольная болезнь печени. Клин гепатол 2012; 8 (2): 33-40.
  53. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57 (2): 399-420.
  54. Лазебник Л.Б., Дроздов В.Н. Заболевания органов пищеварения у пожилых. М: Анахарсис 2003.
  55. Bradley K.A., DeBenedetti A.F., Volk R.J. et al. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res 2007; 31 (7): 1208-1217.
  56. Sorbi D., Boynton J., Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94 (4): 1018-122.
  57. Soresi M., Magliarisi C., Campagna P. et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003; 23 (2C): 1747-1753.
  58. Marrero J.A., Su G.L., Wei W. et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37 (5): 1114-1121.
  59. Elphick D.A., Dube A.K., McFarlane E. et al. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am J Gastroenterol 2007; 102 (4): 780-788.
  60. Lefkowitch J.H. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9 (1): 37-53.
  61. Maddrey W.C., Boitnott J.K., Bedine M.S. et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75 (2): 193-199.
  62. Forrest E.H., Evans C.D., Stewart S. et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54 (8): 1174-1179.
  63. Dunn W., Jamil L.H., Brown L.S. et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-358.
  64. Диетология. Руководство. 3-е изд. Под ред. А.Ю.Баранов­ского. СПб: Питер 2008.
  65. Смолянский Б.Л., Лифляндский В.Г. Диетология. Новейший справочник для врачей. СПб: Сова, М: Эксмо 2003.
  66. Mathurin P., Mendenhall C.L., Carithers R.L. et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-487.
  67. Ramond M.-.J, Poynard T., Rueff B. et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 362: 507-512.
  68. Forrest E.H., Morris A.J., Stewart S. et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56 (12): 1743-1746.
  69. Mathurin P., Abdelnour M., Ramond M.J. et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003; 38: 1363-1369.
  70. Louvet A., Naveau S., Abdelnour M. et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-1354.
  71. Deree J., Martins J.O., Melbostad H. et al. Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo) 2008; 63 (3): 321-328.
  72. McHutchison J.G., Draguesku R.B. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991; 14: 96A.
  73. Akriviadis E., Botla R., Briggs W. et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648.
  74. Boetticher N.C., Peine C.J., Kwo P. et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135 (6): 1953-1960.
  75. Mato J.M., Camara J., Fernandez de Paz J. et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-1089.
  76. Rambaldi A., Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2006; (2): CD002235.
  77. Маев И. Дичева Д., Андреев Д., Пенкина Т. Урсодезоксихолевая кислота в терапии алкогольной болезни печени. Врач 2012; 10: 52-55.
  78. Pelletier G., Roulot D., Davion T. et al. URSOMAF Group. A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice. Hepatology 2003; 37 (4): 887-892.

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies